Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 29;9(7):e002968. doi: 10.1136/jitc-2021-002968

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CD200 protects AML cells from T cell–mediated clearance in vivo. (A, B) Schematic for immunodeficient (A) and PBMC-humanized (B) mouse model systems. (C, D) Tumor growth measured by luciferase imaging of CD200^± OCI-AML3 cells in immunodeficient (C) and PBMC-humanized (D) mice. Gray box indicates background flux levels. (E, F) Overall survival of mice with CD200^± leukemia measured from the day of leukemia injection in immunodeficient (E) and PBMC-humanized (F) models. (G) Fraction of circulating human PBMCs in humanized mice with either CD200^± leukemia or humanized-only controls at day 7 after OCI-AML3 injection. (H) Normalized serum cytokine abundance for each mouse in (G). Multiple t-tests compared cytokine production in CD200⁻ vs CD200⁺ mice. *q<0.05.